ASSENT 3
ASSENT 3
Assessment of the Safety of a New Thrombolytic-3. A clinical trial comparing the efficacy and safety of tenecteplase plus enoxaparin or abciximab with tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction (MI).Conclusion Tenecteplase plus enoxaparin or abciximab reduced ischaemic complications of an acute MI; tenecteplase plus enoxaparin may be a reperfusion regimen warranting further study.